TY - JOUR
T1 - 68Ga-FAPI PET/CT Interobserver Agreement on Tumor Assessment
T2 - An International Multicenter Prospective Study
AU - Mei, Riccardo
AU - Kessler, Lukas
AU - Pabst, Kim M.
AU - Weber, Manuel
AU - Schimdkonz, Christian
AU - Rischpler, Christoph
AU - Zacho, Helle Damgaard
AU - Hope, Thomas
AU - Schwarzenböck, Sarah M.
AU - Allen-Auerbach, Martin
AU - Emmett, Louise
AU - Ferdinandus, Justin
AU - Unterrainer, Marcus
AU - Schaarschmidt, Benedikt M.
AU - Umutlu, Lale
AU - Farolfi, Andrea
AU - Castellucci, Paolo
AU - Nanni, Cristina
AU - Telo, Silvi
AU - Fanti, Stefano
AU - Herrmann, Ken
AU - Fendler, Wolfgang P.
N1 - © 2023 by the Society of Nuclear Medicine and Molecular Imaging.
PY - 2023/7
Y1 - 2023/7
N2 - 68Ga-fibroblast activation protein inhibitors (FAPIs) are promising radiotracers for cancer imaging, with emerging data in the recent years. Nonetheless, the interobserver agreement on
68Ga-FAPI PET/CT study interpretations in cancer patients remains poorly understood. Methods:
68Ga-FAPI PET/CT was performed on 50 patients with various tumor entities (sarcoma [n 5 10], colorectal cancer [n 5 10], pancreatic adenocarcinoma [n 5 10], genitourinary cancer [n 5 10], and other types of cancer [n 5 10]). Fifteen masked observers reviewed and interpreted the images using a standardized approach for local, local nodal, and metastatic involvement. Observers were grouped by experience as having a low (,30 prior
68Ga-FAPI PET/CT studies; n 5 5), intermediate (30–300 studies; n 5 5), or high level of experience (.300 studies; n 5 5). Two independent readers with a high level of experience and unmasked to clinical information, histopathology, tumor markers, and follow-up imaging (CT/MRI or PET/CT) served as the standard of reference (SOR). Observer groups were compared by overall agreement (percentage of patients matching SOR) and Fleiss k with mean and corresponding 95% CI. We defined acceptable agreement as a k value of at least 0.6 (substantial or higher) and acceptable accuracy as at least 80%. Results: Highly experienced observers agreed substantially on all categories (primary tumor: k 5 0.71; 95% CI, 0.71–0.71; local nodal involvement: k 5 0.62; 95% CI, 0.61–0.62; distant metastasis: k 5 0.75; 95% CI, 0.75–0.75), whereas observers with intermediate experience showed substantial agreement on primary tumor (k 5 0.73; 95% CI, 0.73–0.73) and distant metastasis (k 5 0.65; 95% CI, 0.65–0.65) but moderate agreement on local nodal stages (k 5 0.55; 95% CI, 0.55–0.55). Observers with low experience had moderate agreement on all categories (primary tumor: k 5 0.57; 95% CI, 0.57–0.58; local nodal involvement: k 5 0.51; 95% CI, 0.51–0.52; distant metastasis: k 5 0.54; 95% CI, 0.53–0.54). Compared with SOR, the accuracy for readers with high, intermediate, and low experience was 85%, 83%, and 78%, respectively. In summary, only highly experienced readers showed substantial agreement and a diagnostic accuracy of at least 80% in all categories. Conclusion: The interpretation of
68Ga-FAPI PET/CT for cancer imaging had substantial reproducibility and accuracy among highly experienced observers only, especially for local nodal and metastatic assessments. Therefore, for accurate interpretation of different tumor entities and pitfalls, we recommend training or experience with at least 300 representative scans for future clinical readers.
AB - 68Ga-fibroblast activation protein inhibitors (FAPIs) are promising radiotracers for cancer imaging, with emerging data in the recent years. Nonetheless, the interobserver agreement on
68Ga-FAPI PET/CT study interpretations in cancer patients remains poorly understood. Methods:
68Ga-FAPI PET/CT was performed on 50 patients with various tumor entities (sarcoma [n 5 10], colorectal cancer [n 5 10], pancreatic adenocarcinoma [n 5 10], genitourinary cancer [n 5 10], and other types of cancer [n 5 10]). Fifteen masked observers reviewed and interpreted the images using a standardized approach for local, local nodal, and metastatic involvement. Observers were grouped by experience as having a low (,30 prior
68Ga-FAPI PET/CT studies; n 5 5), intermediate (30–300 studies; n 5 5), or high level of experience (.300 studies; n 5 5). Two independent readers with a high level of experience and unmasked to clinical information, histopathology, tumor markers, and follow-up imaging (CT/MRI or PET/CT) served as the standard of reference (SOR). Observer groups were compared by overall agreement (percentage of patients matching SOR) and Fleiss k with mean and corresponding 95% CI. We defined acceptable agreement as a k value of at least 0.6 (substantial or higher) and acceptable accuracy as at least 80%. Results: Highly experienced observers agreed substantially on all categories (primary tumor: k 5 0.71; 95% CI, 0.71–0.71; local nodal involvement: k 5 0.62; 95% CI, 0.61–0.62; distant metastasis: k 5 0.75; 95% CI, 0.75–0.75), whereas observers with intermediate experience showed substantial agreement on primary tumor (k 5 0.73; 95% CI, 0.73–0.73) and distant metastasis (k 5 0.65; 95% CI, 0.65–0.65) but moderate agreement on local nodal stages (k 5 0.55; 95% CI, 0.55–0.55). Observers with low experience had moderate agreement on all categories (primary tumor: k 5 0.57; 95% CI, 0.57–0.58; local nodal involvement: k 5 0.51; 95% CI, 0.51–0.52; distant metastasis: k 5 0.54; 95% CI, 0.53–0.54). Compared with SOR, the accuracy for readers with high, intermediate, and low experience was 85%, 83%, and 78%, respectively. In summary, only highly experienced readers showed substantial agreement and a diagnostic accuracy of at least 80% in all categories. Conclusion: The interpretation of
68Ga-FAPI PET/CT for cancer imaging had substantial reproducibility and accuracy among highly experienced observers only, especially for local nodal and metastatic assessments. Therefore, for accurate interpretation of different tumor entities and pitfalls, we recommend training or experience with at least 300 representative scans for future clinical readers.
KW - Adenocarcinoma
KW - Fluorodeoxyglucose F18
KW - Gallium Radioisotopes
KW - Humans
KW - Observer Variation
KW - Pancreatic Neoplasms
KW - Positron Emission Tomography Computed Tomography/methods
KW - Prospective Studies
KW - Quinolines
KW - Reproducibility of Results
KW - cancer imaging
KW - fibroblast activation protein
KW - FAPI
KW - interobserver agreement
KW - PET
UR - http://www.scopus.com/inward/record.url?scp=85164210361&partnerID=8YFLogxK
U2 - 10.2967/jnumed.122.265245
DO - 10.2967/jnumed.122.265245
M3 - Journal article
C2 - 37230530
SN - 0161-5505
VL - 64
SP - 1043
EP - 1048
JO - The Journal of Nuclear Medicine
JF - The Journal of Nuclear Medicine
IS - 7
M1 - 265245
ER -